Why Halozyme Therapeutics, Inc. Deserves Its 52-Week High
In response to the company posting pleasing third-quarter results and boosting guidance, shares of Halozyme Therapeutics (NASDAQ: HALO), a biotech that focuses on making other drugs more effective, jumped 13% as of 1:45 p.m. EST.
Here's an overview of the headline numbers from the quarter.
The upbeat quarterly results enabled management to make a number of positive changes to its full-year guidance:
Source: Fool.com
Halozyme Therapeutics Inc. Stock
€53.94
-2.240%
With 25 Buy predictions and not a single Sell prediction Halozyme Therapeutics Inc. is an absolute favorite of our community.
With a target price of 58 € there is a slightly positive potential of 7.53% for Halozyme Therapeutics Inc. compared to the current price of 53.94 €.
